News & Views | Published:

Schizophrenia drug says goodbye to dopamine

Nature Medicine volume 13, pages 10181019 (2007) | Download Citation

Subjects

A drug that activates glutamate receptors offers promise for a new class of anti-psychotic therapeutics and sheds light on the pathophysiology of this devastating disease (pages 1102–1107).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Acta Pharmacol. Toxicol. (Copenh.) 20, 140–144 (1963).

  2. 2.

    , & Science 192, 481–483 (1976).

  3. 3.

    et al. Nat. Med. 13, 1100–1105 (2007).

  4. 4.

    Anonymous. Nature 336, 95–96 (1998).

  5. 5.

    , , , , & Neuron 52, 139–153 (2006).

  6. 6.

    & Mol. Psychiatry 10, 40–68 (2005).

  7. 7.

    et al. J. Biol. Chem. 282, 24343–24351 (2007).

  8. 8.

    et al. Proc. Natl. Acad. Sci. USA 101, 12604–12609 (2004).

  9. 9.

    et al. Eur. J. Neurosci. 17, 2106–2118 (2003).

  10. 10.

    et al. Arch. Gen. Psychiatry 51, 199–214 (1994).

  11. 11.

    et al. N. Engl. J. Med. 353, 1209–1223 (2005).

  12. 12.

    & Trends Neurosci. 27, 683–690 (2004).

Download references

Author information

Affiliations

  1. Daniel R. Weinberger is at the Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA. daniel.weinberger@mail.nih.gov

    • Daniel R Weinberger

Authors

  1. Search for Daniel R Weinberger in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0907-1018

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing